Literature DB >> 19168875

Metastatic adrenocortical carcinoma treated with sunitinib: a case report.

Jeong-Ok Lee1, Keun-Wook Lee, Chung-Jong Kim, Yu Jung Kim, Hee Eun Lee, Haeryoung Kim, Jee Hyun Kim, Soo-Mee Bang, Jae-Sung Kim, Jong Seok Lee.   

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19168875     DOI： 10.1093/jjco/hyn146

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


  10 in total

1.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

2.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

Review 3.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

4.  Giant non-functioning adrenocortical carcinoma: A rare childhood tumor.

Authors:  Viral V Patel; Diva S Shah; Chandra R Raychaudhari; Keyuri B Patel
Journal:  Indian J Med Paediatr Oncol       Date:  2010-04

5.  The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

Authors:  Ciara O'Sullivan; Maureen Edgerly; Margarita Velarde; Julia Wilkerson; Aradhana M Venkatesan; Stefania Pittaluga; Sherry X Yang; Dat Nguyen; Sanjeeve Balasubramaniam; Tito Fojo
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

6.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

7.  Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Miriam Reuss; Dorothee Kühner; Sarah Johanssen; Melanie Beyer; Martina Zink; Michaela F Hartmann; Vivek Dhir; Stefan A Wudy; Wiebke Arlt; Silviu Sbiera; Bruno Allolio; Martin Fassnacht
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-09       Impact factor: 5.555

8.  The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.

Authors:  Elaine Silveira; Isadora Pontes Cavalcante; Jean Lucas Kremer; Pedro Omori Ribeiro de Mendonça; Claudimara Ferini Pacicco Lotfi
Journal:  Cancer Cell Int       Date:  2018-03-01       Impact factor: 5.722

9.  A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma.

Authors:  Maryam Lotfi Shahreza; Nasser Ghadiri; James R Green
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

10.  Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.

Authors:  Sudheer Kumar Gara; Justin Lack; Lisa Zhang; Emerson Harris; Margaret Cam; Electron Kebebew
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.